SecBot SecBot
SECBOTREPLAY Home › Report › PROK

PROK · ProKidney reported Q2 2026 financial results with no revenue or EPS…

ProKidney · PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Aug 10, 2026 at 16:05 ET

ProKidney reported Q2 2026 financial results with no revenue or EPS guidance to analyze, as the company is pre-commercial. The key highlight is completing enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis, with topline eGFR slope results expected in Q2 2027, a major derisking milestone. Cash burn continues, with $181.6 million in cash as of June 30, 2026, down from $224.9 million in Q1 2026, providing runway into mid-2027.

  • Completed enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis
  • Topline eGFR slope results anticipated in Q2 2027
  • On track for full enrollment of ~470 patients in PROACT 1 in H2 2026
  • Cash, cash equivalents, and marketable securities: $181.6 million at June 30, 2026 (vs $224.9 million at March 31, 2026)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access